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the disease is 120 million with over a third of those affected
having severe chronic disease. We attempted to estimate the
actual disease burden in three countries, with varying levels of
disease prevalence, so that the impact of LF in these countries
can be better understood. METHODS: We constructed an eco-
nomic model of work lost due to LF in three countries where it
is prevalent (India, Ghana, and Thailand). Data sources included
published studies on productivity among individuals who expe-
rience LFs debilitating manifestations in the form of acute ade-
nolymphangitis [(ADL) or chills and fevers often with swelling
of the affected limb and associated lymph node inﬂammation]
and chronic lymphatic obstruction (which can lead to hydrocele
and elephantiasis). Wages used for our calculations were the
minimum agricultural wages obtained from the International
Labor Organization and converted to 2005 US$. The time
horizon used was one year. RESULTS: The estimated period
prevalence of chronic lymphatic obstruction secondary to LF
among people between the ages of 15–65 years in India, Ghana
and Thailand was estimated at approximately 77,779,036;
1,917,923; and 549,733 respectively. Wages lost attributable to
lymphatic obstruction were estimated to be $4.5 billion; $261
million; and $174 billion respectively. Additional annual wages
lost attributable to ADL are approximately $22 million; $1
million; and $855,150 in these countries respectively. CON-
CLUSION: The model demonstrated that LF results in signiﬁ-
cant and costly work impairments. As one of only six global
diseases that meet the criteria for being eradicable, our research
on the economic impact of LF suggests that policymakers should
make investments in initiatives aimed at preventing and treating
this disease.
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OBJECTIVE: To determine the prevalence of organ-threatening
and mental health co-morbidities and examine their effects on
total medical costs in systemic lupus erythematosus (SLE)
patients. METHODS: A total of 2395 California Medicaid
patients with a diagnosis of SLE were included in this retro-
spective analysis. Diagnosis of mental co-morbidities (depres-
sion, anxiety, and fatigue) was based on ICD-9 codes from the
claims record as was the presence of organ involvement (heart,
lung, kidney, liver, and serious blood involvement). The analyses
were conducted from an insurer’s perspective; payments were
used as a proxy measure for costs. Total medical costs included
inpatient costs, ambulatory and outpatient costs, prescription
costs, and nursing facility/intermediate care facility costs.
Descriptive analysis was performed to determine the prevalence
of these co-morbidities. The effect of mental and organ-threat-
ening co-morbidities on total medical costs of SLE patients was
modeled using a mixed regression estimation controlling for age,
gender, ethnicity, and eligibility in both Medicaid and Medicare.
RESULTS: The incidence rates for depression, anxiety and
fatigue were 14.7%, 8.2%, and 15.8%, respectively. About 37%
of the patients have at least one affected organ. Pulmonary man-
ifestation was the most common organ involvement, occurring
in 20.4% of the SLE patients. About 11% of the patients 
had kidney involvement while 18% had heart involvement.
Higher incidence rates of fatigue was observed in patients with
organ-threatening SLE (21.6% vs. 12.5%, p < 0.01). Organ-
involvement results in an average increase of $1144/per month
in total medical costs (p < 0.01). Among the three mental co-
morbidities, fatigue is signiﬁcantly associated with increased
total costs of $536 (p < 0.0001). The ethnicity inﬂuence on total
medical costs dissipates with the inclusion of organ-threatening
co-morbidities and fatigue. CONCLUSIONS: Both mental
health and organ involvement co-morbidities are signiﬁcant pre-
dictors of medical costs of treating SLE.
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OBJECTIVES: Examine frequency and costs of disability among
employed individuals with COPD. METHODS: Retrospective
analysis of disability and medical claims data for employees of
nine national self-insured companies. Active employees 
40–63 years old with diagnosis of COPD (ICD-9-CM: 491.xx,
492.x,496) between January 1, 2001–December 31, 2003 were
identiﬁed. Index date was later of: 1) ﬁrst COPD diagnosis, or
2) ﬁrst date of eligibility for short-term disability (STD), long-
term disability (LTD), and health beneﬁts. Employees with cystic
ﬁbrosis, lung cancer, tuberculosis, or pregnancy, and those con-
tinuously eligible for <90 days following index date, were
excluded. Using propensity score matching, controls were
matched 2 :1 to COPD subjects on age, gender, geographic
region, employer, length of employment, and salary range. Sub-
jects were followed until the earliest of non-active employee
status, disenrollment from any beneﬁt, 365 days of follow-up,
or March 31, 2004. Likelihood of disability was compared
between COPD subjects and controls using logistic regression,
adjusting for length of follow-up and speciﬁc comorbidities. Indi-
rect costs of disability, measured as disability days multiplied by
subjects’ daily wage, were compared among subjects with a dis-
ability claim using GLM with a gamma distribution and log link,
adjusting by the aforementioned covariates. RESULTS: Mean
length of follow-up for COPD subjects (n = 1349) and controls
(n = 2696) was 220 and 233 days. Mean age was 52 years, and
cohorts approximately 50% male. All comorbidities were more
common in the COPD cohort. A greater proportion of COPD
subjects used STD (21.8% vs. 7.0%), LTD (2.4% vs. 0.4%), 
or any disability beneﬁt (22.8% vs. 7.3%). Odds ratios for like-
lihood of disability for COPD subjects were: STD, 2.11 (95%
CI: 1.64–2.71); LTD, 4.21 (1.93–9.16); any disability, 2.15
(1.68–2.75). CONCLUSIONS: Among those with disability
(307 COPD patients, 197 controls), indirect costs were higher
among COPD subjects ($8559) than controls ($5443); this
approached signiﬁcance (p = 0.07).
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OBJECTIVES: The Australian national reimbursement system
has tended to evolve independently from other health care
funding environments. Over the past few years, a range of policy
initiatives has been introduced. Many of these have been aimed
directly at restricting the growth in drug expenditures.
METHODS: This study examines the range of initiatives and
estimates the savings that each has produced. The authors have
built a large relational database that captures all pricing, utili-
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sation and committee decisions. These data were analysed to
determine the impact of the policy measures. Policy changes
included increased patient co-payments, mandatory 12.5% price
cut with generic entry, a weighted average monthly treatment
cost price adjustment mechanism. The Pharmaceutical Beneﬁts
Advisory Committee controls recommendations to government
concerning the funding of new drugs. RESULTS: The level 
of acceptance of new drugs that are submitted on a cost-
effectiveness basis has fallen to approximately 20%. The impact
of patient co-payment on reducing the volume of units sold
nationally was estimated to be 5–10%. The effect of price 
reduction initiatives in 2005 on Pharmaceutical Beneﬁts Scheme
expenditure was estimated at 3–4% of total spending. CON-
CLUSIONS: These initiatives have been very effective in restrict-
ing national drug expenditures growth. For most of the 1990s
and into this decade, total expenditure has grown more than
10% per annum. By the end of 2005 this had fallen to well below
5%.
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OBJECTIVE: To identify the impact and persistence of bariatric
surgery on health outcomes and pharmacological treatments
among obese patients. METHODS: A comprehensive analysis of
4322 patients with a diagnostic of obesity (ICD-9-CM = 278)
and a CPT code of bariatric surgery (43,842, 43,843, 43,846,
43,847, S2085) was conducted using US administrative claims
data covering 5.0 million lives. The 50 most frequent 3 digit
ICD-9-CM codes prior to surgery were analyzed along with cor-
responding pharmacological treatments. Diagnostics and phar-
macological treatment were then compared in the 90 days
preceding the surgery and eight 90 day post-surgery periods
(days 30–120 to days 660–750). Frequency counts pre- and post
surgery were performed using 3 digit ICD-9-CM codes for 
diagnostics and AHFS (American Hospital Formulary Service)
therapeutic classes and compared using chi-squared tests.
RESULTS: Cardiovascular disease, diabetes, respiratory disease
(and asthma in particular), joint and muscle disease, and psy-
chiatric disorders prevalence fell monotonically over the two
year period observed (mean age = 43.2, 16.4% male). Two years
following surgery, cardiovascular disease prevalence decreased
from 40.4% to 5.7%), diabetes mellitus from 18.6% to 3.1%,
respiratory disease from 45.0% to 3.2% with asthma dropping
from 6.7% to under 1%, diseases of the joints and muscles from
24.7% to 7.4%, and psychiatric disorders from 12.1% to 3.7%.
Anemia diagnoses increased from 4.1% to 8.9% after 210 days,
but decreased back to 3.6% after 750 days. Treatment frequency
with insulin and oral antidiabetics decreased from 4.4% to 0.5%
and from 16.0% to 1.8%, respectively. Treatment frequency for
cardiovascular diseases (Ace inhibitors, calcium channel block-
ers, diuretics, betablockers, and other hypotensives) fell from
42.1% to 10.1%. Hypolipidemic use also dropped from 12.6%
to 1.9%. All differences between pre- and post surgery propor-
tions are statistically signiﬁcant (P = 0.05). CONCLUSION:
Bariatric surgery is associated with signiﬁcant improvements in
health outcomes and reduced pharmacological utilization for
major disease categories.
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OBJECTIVES: This study examines the factors that inﬂuence
generic entry upon patent expiration of branded drugs, speciﬁ-
cally focusing on the drug’s proﬁtability as a generic ﬁrm’s incen-
tive to enter as well as additional patents ﬁling as a strategic entry
barrier tool by patent holders. METHODS: For 138 drugs
(approved through NDA process between 1970 and 1990)
whose initial patent expired over the period 1994–2003, the
expiration dates of all related patents listed and their generic
version’s approval dates (if generic entry happened) were
obtained from the FDA. At different follow-up time point—6,
12, 18, and 24 months after the initial patent expiration, probit
analyses of the likelihood of generic entry were done to identify
the determinants of the entry. Additionally, we examined the
relationship between total number of patents listed and the
drug’s proﬁtability using negative binomial regression analysis to
investigate whether patent holders ﬁled more patents for future
top-selling products. RESULTS: Top-selling drugs as well as the
drugs for geriatric care were more likely to attract generic entry
at every time point (Relative Risk (RR) for top-selling drugs =
33.84, 6.76, 6.04, and 3.90; RR for geriatric drug = 3.97, 2.35,
1.82, and 1.43 respectively). The likelihood of generic entry
increased as the initial patent expiration year increased (p <
0.05). Generic competition was less likely to occur under the
presence of any unexpired additional patent(s) at each time point
(RR = 0.13, 0.33, 0.30 and 0.32). Top-selling drugs had more
patents compared to non-top-selling drugs (p < 0.000). CON-
CLUSIONS: Delay in generic competition was associated with
patent holder’s intention to extend patented period by ﬁling more
patents. The generic industry has targeted top-selling products
and future-growing market as the population ages. Generic com-
petition increased under “favoring generics policy” and “cost
containment efforts” in last decade.
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OBJECTIVE: Approximately 30% of elderly do not have pre-
scription drug coverage. To remedy this problem, the Medicare
Modernization Act was recently passed. Surprisingly, little is
known about how drug coverage will affect health. The goal of
this paper is to obtain estimates of “causal effects” of prescrip-
tion drug coverage on drug use, inpatient visits and health of the
elderly. METHODS: The primary data source used in the analy-
ses is the Medicare Current Beneﬁciary Survey (MCBS), Cost and
Use ﬁle from Centers for Medicare and Medicaid Services (CMS)
for years 1992–2000. Two empirical approaches were used to
account for non random sorting into drug coverage: ﬁxed-effects
and instrumental variables (IV). The Fixed-effect approach uses
longitudinal data and controls for unmeasured person-speciﬁc
effects that may confound the relationships of interest. IV uses
arguably exogenous variation in prescription drug coverage to
obtain estimates of the relationships of interest. RESULTS:
Between 1992–2000 approximately 25% of the elderly in the
sample gained some level of prescription drug coverage. Esti-
mates showed that after accounting for the non-random nature
of prescription drug coverage, drug coverage, particularly public
coverage, signiﬁcantly increased the utilization of prescription
drugs (~13% higher utilization), but has no signiﬁcant discern-
able effect on the use inpatient visits or health, as measured by
